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The world has experienced some very large shifts in
the epidemiology of carbon monoxide poisoning,
but it remains one of the most important
toxicological global causes of morbidity and mortality.
The diagnosis can be quickly confirmed with blood
gases (pulse oximeters lack both sensitivity and
specificity). Several strong predictors for serious
neurological sequelae (prolonged loss of consciousness
and elevated S100B) and reduced life expectancy
(elevated troponin) are now reasonably well established.
Despite this clearly defined high-risk group and extensive
research into the pathophysiology, there has been
little translation into better treatment. Much of the
pathophysiological research has focused on hyperbaric
oxygen. Yet it is apparent that clinical trials show little
evidence for benefit from hyperbaric oxygen, and
the most recent even raises the possibility of harm
for repeated courses. More logical and promising
potential antidotes have been under-researched,
although recently both animal and small human studies
suggest that erythropoietin may reduce S100B and
prevent neurological sequelae. Major breakthroughs
are likely to require further research on this and other
treatments that may inhibit post-hypoxic inflammatory
responses and apoptosis.deaths often outnumber admissions [5]. It is thereforeReview
Carbon monoxide (CO) results from the incomplete
combustion of carbon-containing substances and is a
colorless, odorless, and tasteless gas [1]. Exposure is
most commonly from car exhaust (unleaded petrol cars
produce about one tenth the amount of CO of older
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2014It is clear that the epidemiology is driven by the source
of CO and the diagnostic definitions applied. Notably, in
the US, there appears to be quite a different pattern,
with extremely large numbers of patients diagnosed but
a relatively low death rate; for example, it was estimated
that there were 1,000 to 2,000 accidental deaths due to
CO exposure each year, resulting from an estimated
50,000 annual exposures [2]. The US case fatality of less
than 5% for a poisoning that is highly lethal in most
other countries may reflect several factors. Firstly, poi-
soning is largely from domestic heating (compare with
fire or suicide) and is diagnosed (and treatment given)
sometimes in the absence of any significant elevation of
carboxyhemoglobin (COHb). For example, poison center
calls in the National Poison Data System (2000 to 2009)
found that 45.1% of the 68,316 unintentional, non-fire-
related, CO exposures were managed at the site of
exposure (that is, without any confirmation) [3]. Even of
those attending a hospital and referred for hyperbaric
oxygen (HBO), 10% had an initial COHb within the
normal range for heavy smokers (<10%) and less than
1% had a recorded COHb over 50% [4].
This experience contrasts with most other countries
where fires and suicidal poisoning (car exhaust or char-
coal) are the leading causes of diagnosed CO poisoning.
In Australia, for example, accidental poisoning accounts
for less than 10% of calls about CO poisoning and the
much easier to compare countries and examine trends
over time by examining trends in CO poisoning deaths.
Several Asian countries are facing rapidly evolving epi-
demics of CO poisoning from suicide by charcoal burn-
ing [6]. This increase occurred in the late 1990s, after a
much publicized case in the media of a 38-year-old
Hong Kong woman who committed suicide in a sealed
bedroom by burning barbecue charcoal. The media
depicted this means of suicide as painless and non-
violent. Subsequently, in Hong Kong and Taiwan, there
has been an increasing incidence of charcoal burning
suicides, which has led to an overall increase in the
suicide rate of approximately 20% [6,7]. A strategy to
reduce the risk of misuse of charcoal burners is urgentlyentral Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gas and catalytic convertors has demonstrated that
means restriction can be extremely effective in reducing
CO suicides [8-10]. A range of possible solutions may
need to be tried given the practical difficulties of restric-
ting suicidal use of widely available domestic cooking
equipment. On a more positive note, many countries
have seen a substantial reduction in lethal car exhaust
poisoning with the rise of catalytic converters [8,11].Mechanisms of toxicity
The most clearly established mechanisms for CO to-
xicity relate to tissue hypoxia. CO binds to hemoglobin
with an affinity 200 to 240 times that of oxygen [12]. As
COHb cannot carry oxygen, this leads to reduced
oxygen-carrying capacity. Furthermore, COHb increases
the affinity of the remaining sites for oxygen, meaning
that oxygen release by the remaining oxygenated
hemoglobin is also impaired. Thus, CO leads to im-
paired oxygen delivery to tissues and eventually to
marked tissue hypoxia when compensatory mechanisms
to maintain oxygen delivery fail.
However, tissue hypoxia is not the only possible
explanation for the toxic effects seen. CO causes harm
by both oxidative stress that follows a period of hypoxia
and cellular damage by inflammatory processes. CO
binds to and inhibits mitochondrial cytochrome oxidase,
thereby directly inhibiting aerobic metabolism (analo-
gous to the effect of cyanide). In the brain, CO binds to
cytochrome c oxidase, which results in impairment of
ATP synthesis and increased production of reactive oxy-
gen species [13,14]. Inflammatory changes in acute CO
poisoning include intravascular neutrophil activation
due to interactions with platelets. This leads to neutro-
phil degranulation and perivascular oxidative stress [15].
While in rat models, CO exposure has been shown to
precipitate abnormalities in myelin basic protein due to
reactions with lipid peroxidation products [16]. Further-
more, some damage may be caused by the marked oxi-
dative stress, free radical production, inflammation, and
apoptosis seen when oxygenation improves and CO
concentrations fall after severe poisoning (analogous to
reperfusion injury) [15].
Unfortunately, much of the evidence on these effects
has not used positive controls (that is, hypoxic injury
not due to CO), and it is unclear whether such processes
differ in any meaningful way from similar effects seen
with reperfusion injury [17]. It is clear that organs with
the highest oxygen demand are the most susceptible to
injury, and brain and cardiac effects dominate acute cli-
nical features and also risk assessment for late or per-
manent effects. There is potential for both serious
delayed neurotoxicity (including Parkinsonism andmemory and concentration impairment) and cardio-
toxicity (myocardial injury and reduced life-expectancy).
It is also apparent that many of the early non-specific
clinical effects (for example, headache, nausea, and
tachycardia) occurring at COHb concentrations of less
than around 40% are likely to be signs of compensatory
homeostatic responses rather than tissue hypoxemia. To
maintain oxygen delivery to the brain, a large compensa-
tory increase in cardiac output is required (as at altitude
or with anemia). Unfortunately, any rise in cardiac out-
put and respiratory rate also greatly accelerates CO up-
take. At a critical COHb and time point, which likely
varies considerably between individuals, the heart be-
comes unable to deliver a cardiac output great enough
to compensate for the reduced oxygen-carrying capacity.
At this stage, cardiac hypoxia will reduce cardiac output
and exacerbate severe tissue hypoxia and death will ra-
pidly occur unless there is intervention (Figure 1). The
signs and investigations indicating that this critical tip-
ping point has been passed (that is, more than transient
loss of consciousness and elevated neuronal or cardiac
injury biomarkers) have all been established as strong
markers of short- and long-term prognosis [18-20]. The
ability of the individual to compensate for the decreased
oxygen-carrying capacity determines the level at which
these more severe manifestations become apparent,
and those with underlying anemia or respiratory, car-
diac, or vascular disease may develop severe toxicity at
lower concentrations.
Long-term sequelae and prognostication
The long-term consequences in survivors can range from
severe brain damage (which is fortunately uncommon)
to a much more common syndrome of less severe but
persistent problems. Neurological sequelae are often
divided into persistent neurologic sequelae (PNS) and
delayed neurologic sequelae (DNS) [1,21]. The incidence
of neurological sequelae depends very much on the
definition applied, the extent and timing of the as-
sessment, and the population studied.
The concept of persistent neurological injury after a
hypoxic brain injury is straightforward. DNS, in contrast,
lacks a consistent definition, diagnostic criteria, or an
established mechanism. However, the apparent develop-
ment of the first neuropsychological symptoms or signs
occurring days to weeks after CO poisoning clearly oc-
curs. DNS varies very widely in studies from a few per-
cent to two thirds of patients [22-25]. However, the ratio
of DNS to PNS appears much lower when studies are
prospective and careful monitoring is done from the be-
ginning (that is, DNS may sometimes reflect delayed
diagnosis rather than delayed appearance of symptoms).
Neurological sequelae are most commonly subjective
and affect mood, short-term memory, attention, and
Figure 1 Carboxyhemoglobin (COHb) versus oxygen delivery
capacity of the blood and increased cardiac output required
to deliver the same amount of oxygen. (a) This is shown with a
linear progression in COHb. (b) In the more likely scenario, there is
continuous exposure to COHb and the rate of uptake of COHb is
roughly proportional to cardiac output, resulting in a very rapid
deterioration to life-threatening poisoning, after a relatively long
mild poisoning stage. CO, carbon monoxide; O2, oxygen.
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tered are depressed mood (even in those accidentally
exposed) and difficulty with higher intellectual functions
(especially short-term memory and concentration). More
severe problems include areas typically affected by
‘watershed’ infarcts (for example, basal ganglia and
memory). In some cases, these are not noted initially but
present later after initial recovery (typically within aweek of the exposure). Neuro-psychological testing may
be useful to provide objective measures of subtle deficits
not found with routine bedside mental state examination
and also to monitor the progress of these sequelae.
Long-term follow-up is necessary in those at risk, as
more subtle defects can develop or become apparent
over a few weeks to months. However, the long-term
prognosis is favorable in the majority of cases, and
symptoms gradually resolve over the first few months
[26], and the overwhelming majority of patients with
CO poisoning return to full-time work [27].
Identification of patients who are at risk of neuro-
logical sequelae serves an important role in terms of
counseling and indicating the extent of follow-up war-
ranted. The best identified risk factors for long-term
neurological effects are early and obvious neurological
damage or a sustained loss of consciousness during the
CO exposure. Most studies have found that significant
neuropsychological sequelae are confined largely to
those who have loss of consciousness at some stage
[27-29]. However, if less stringent criteria are used for
neurological sequelae (that is, slightly low test scores),
other risk factors are thrown up by univariate analysis
(for example, prolonged or repeated exposures and older
age). These risk factors may also represent confounding,
or reverse causality (for example, older age is linked to a
higher risk of poor memory and executive function
irrespective of CO poisoning; and impaired cognition
prior to exposure is a risk for prolonged or repeated CO
exposures) [28]. The recent promulgation of such cri-
teria as age of more than 36 years (irrespective of the
absence of other more established risk factors) to guide
risk assessment [26,28] or to alter treatment has little to
recommend it; it greatly inflates the numbers perceived
to be at risk and goes against the much stronger evi-
dence of a relatively benign long-term outcome for CO
poisonings without the established risk factors.
However, other objective ways to identify patients at
risk of sequelae are also required, as the history of loss
of consciousness may be complicated in some settings.
Neuron-specific enolase (NSE) is a glycolytic enzyme
that is localized primarily to the neuronal cytoplasm in
the central nervous system. S100B is a calcium-binding
protein localized to astroglial cells [30]. They are both
released after hypoxic damage as a result of neuronal
and astroglial cell death [31]. These markers show con-
siderable promise as intermediate outcome measures
for brain injury in both animals [32] and humans [19].
Studies to date in acute CO poisoning confirm this
promise. In one recent Taiwan study, 10 out of 71
patients developed DNS. These patients not only had
longer loss of consciousness but also had 15-fold higher
S100B levels. Further statistical analysis demonstrated
that this was an independent predictor of the
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S100B of more than 0.165 μg/L predicted DNS with a
sensitivity of 90% and a specificity of 87% (odds ratio
121, 95% confidence interval 4 to 3,467) [19]. The timing
of S100B measurement is critical in interpretation, and
high initial levels were associated with coma and cardiac
injury but these dropped fourfold within 6 hours [33].
This and other studies have reported generally lower
levels and only a minor association with CO poisoning
with loss of consciousness but without such sequelae
[34]. Further larger and long-term studies including
more people with severe poisoning are required to clar-
ify the optimal timing and threshold and the extent to
which a normal S100B can be regarded as reassuring
with respect to long-term prognosis. In general, results
for NSE have shown a less obvious relationship to seve-
rity than S100B [33,34], although one study found that it
was better linked to level of consciousness and also had
a longer apparent half-life [30]. No studies to date have
examined the relationship between NSE elevation and
long-term sequelae.
Toxicity assessment
The severity of poisoning is a function of the duration of
exposure, the ambient concentration of CO, and the
underlying health status of the exposed individual.
COHb concentrations are a rough guide to the severity
of exposure. Venous COHb levels predict arterial levels
with a high degree of accuracy, and the difference
between the two is unlikely to exceed 1% to 2%
COHb [35].
Though useful for diagnosis when detected, the first
measured COHb is not a reliable way to measure sever-
ity or predict long-term outcome [28,36]. The COHb
measurement is often delayed. Furthermore, backwards
extrapolation based on estimated half-life performs
poorly. This is likely because of undefined factors in the
highly variable elimination half-life, which depends on
not only inhaled oxygen but also cardio-respiratory func-
tion. For example, isocapnoic-induced hyperventilation
can increase CO elimination to the same extent as HBO
[37].
The potential use of non-invasive pulse CO oximeters
to obtain rapid, continuous, and field measurements for
triage and monitoring has much appeal. There is a Food
and Drug Administration-approved device (Masimo
Rad-57 signal extraction pulse CO oximeter), but the
pre-registration studies tested the accuracy of this ma-
chine using only healthy volunteers and COHb levels up
to 15% [38]. Later clinical studies suggest that the ma-
chine should not be used, unless blood gases are not
available. For example, in 120 patients presenting to an
emergency department with simultaneous blood gases
and pulse CO oximetry, the limits of agreement of thedifferences in measurement were −11.6% and 14.4%
COHB. This greatly exceeds the ± 5% COHB defined as
a clinically acceptable difference. Furthermore, a third of
patients had a difference between their results of greater
than ± 5% COHb, and the RAD-57 device detected
COHb of only more than 15% with a sensitivity of 48%.
Such results mean that the device clearly cannot be used
to replace standard laboratory measurements or even
triage those requiring formal measurements [39]. The
role of this device may be restricted to situations in
which detection of chronic low level exposures leading
to COHb of less than 15% might serve an occupational
health role.
The standard method to assess severity of exposure is to
focus on neurological and cardiac symptoms indicating
tissue hypoxia, such as loss of consciousness and chest pain.
Objective evidence of ischemic damage may manifest with
neurological signs, but detection of cardiac ischemia re-
quires investigations looking for electrocardiography (ECG)
changes and cardiac enzyme elevation (that is, troponin and
CK-MB). Myocardial injury is very common, particularly in
those with loss of consciousness or underlying vascular
disease or both [40]. A prospective study of transthoracic
echocardiography on 40 patients with CO exposure found
that 50% had left ventricular systolic dysfunction. On repeat
testing in 3 days, the majority (80%) had completely recov-
ered [41]. These changes are not usually simply uncovering
pre-existing coronary artery disease. In one small study, all
coronary angiograms in 20 patients with elevated cardiac
markers following CO poisoning showed normal coronary
arteries [42].
Directly attributable long-term cardiac consequences
(for example, ischemic cardiomyopathy) are unusual;
however, a much higher mortality rate has been reported
in those with a troponin rise after CO poisoning [20]. It
is currently unclear whether this represents long-term
cardiac sequelae or whether these markers occurred in
those with underlying cardiovascular risk factors.
Management
The widely endorsed aspects of management include
removing the patient from the source of exposure and
administering oxygen. Management should include the
following:
 100% oxygen by non-re-breather mask (or ventilator)
as soon as possible. Four to six hours of 100%
normobaric oxygen will remove over 90% of the CO.
 Assessment of severity and potential for coexistent
poisonings as above, including 12 lead ECG and
electrolytes, full blood count, and COHb.
 Supportive care: ensure that the airway is
maintained for those with impaired consciousness,
with intubation if necessary; ensure that the patient
Figure 2 Elimination of carboxyhemoglobin with various
oxygen therapies. (a) Theoretical elimination of
carboxyhemoglobin (COHb) after removal from source and given
hyperbaric oxygen (HBO) versus other oxygen therapies. (b)
Elimination of COHb after removal from the source, receiving high-
flow oxygen and following a typical delay of 2 hours to be given
HBO versus other oxygen therapies. ATM, standard atmospheres;
O2, oxygen.
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increases oxygen demand.
 Obtain serial ECG and cardiac enzymes in patients
with a history of sustained loss of consciousness,
cardiovascular disease, chest pain, or ECG changes.
The main therapeutic goal is to prevent acute and
chronic neuropsychiatric consequences. Oxygen is the
most important treatment and is always indicated for at
least 6 hours. Oxygen toxicity is unlikely with less than
24 hours of treatment. Currently, the evidence for any
treatment beyond 100% oxygen is very weak [43].
Hyperbaric oxygen
HBO therapy is defined as the breathing of 100% oxygen
by patients within hyperbaric chambers compressed to
greater than 1.4 atm of absolute pressure. The half-life
of CO in room air is around 4 to 5 hours. These half-life
values decrease to approximately 40 to 80 minutes with
administration of ‘100% oxygen’ and to 23 minutes when
hyperbaric (2 atm) oxygen is used (Figure 2a). However,
given that the half-life is only around 90 minutes with
high-flow oxygen and that it typically takes at least
2 hours to arrange HBO treatment [4,44], the biological
rationale that HBO is a more effective means of remov-
ing CO in practice is limited (Figure 2b).
It has been suggested that HBO may decrease the risk
of neuropsychiatric sequelae due to other mechanisms
not dependent on enhancing CO elimination. However,
HBO might also feasibly increase oxidative stress during
recovery and is substantially more expensive than nor-
mobaric oxygen. Furthermore HBO therapy can occa-
sionally be complicated by barotrauma [21], seizures
[45], pulmonary edema, and claustrophobia. It is contra-
indicated if there has been chest trauma or if the patient
requires close monitoring or is non-cooperative.
The term HBO therapy covers a broad range of treat-
ments; one survey of North American hyperbaric facil-
ities found 18 different protocols. Among these
protocols, the shortest period of compression lasts 46
minutes whereas the longest lasted 3 hours [46]. Some
centers use multiple compressions over several days. All
of these protocols are lacking evidence to support their
choice over any other protocol or indeed that they im-
prove outcomes in human poisoning.
The stated goal of hyperbaric treatment is the preven-
tion of long-term and permanent neurocognitive dys-
function; no study has yet demonstrated a reduction in
mortality [47,48]. A 2011 systematic review (Cochrane
collaboration) identified six randomized clinical trials
that have compared HBO versus normobaric 100% oxy-
gen [43]. Four of these studies reported negative and
two positive outcomes at 4 to 6 weeks. The negative
studies had mostly subjective outcome measures ofneurological recovery and may feasibly have overlooked
clinically important benefits. In contrast, it was evident
that there was a high risk of bias from the approach to
analysis applied in the positive studies. The largest posi-
tive trial was prematurely stopped ‘for benefit’ but des-
pite this would have been a ‘negative’ study but for the
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ing a change in the primary outcome) that all favored
showing benefit from HBO [22]. Furthermore, a recent
study comparing one versus two HBO sessions in coma-
tose patients found more neurological sequelae in the
group with repeated HBO [27] (Figure 3).
The role of HBO in the acute management of patients
with very severe CO poisoning, such as coma, seizures,
severe metabolic acidosis, or cardiac dysfunction, is par-
ticularly unclear as controlled clinical trials have fre-
quently excluded such patients. If rapidly available, HBO
may be the most effective mechanism for treating hyp-
oxia in such patients; however, it may also be difficult to
use unless a multi-person chamber is available so that
medical/nursing care can continue uninterrupted.
Even among those advocating HBO, controversy exists
about the indications for use of HBO in CO poisoning.
Recommendations for the use of HBO in CO poisoning
vary greatly between guidelines. The American College
of Emergency Physicians clinical guidelines committee
state: ‘HBO is a therapeutic option for CO-poisoned pa-
tients; however, its use cannot be mandated. No clinical
variables, including COHb levels, identify a subgroup of
CO-poisoned patients for whom HBO is most likely to
provide benefit or cause harm’ [49]. Similarly, the Na-
tional Institute for Health Care Excellence: Clinical
Knowledge Summaries advise treatment with 100% oxy-
gen, preferably via a face mask with reservoir. They do
not currently recommend treatment with HBO, as ‘there
is insufficient evidence’ that HBO ‘improves long-term
outcomes of people with severe carbon monoxide poi-
soning, compared with standard oxygen treatment’ [50].
In contrast, the Undersea and Hyperbaric Medical So-
ciety has much broader recommendations and suggests
HBO therapy for patients with serious CO poisoning, asFigure 3 Forest plot of treatment effects seen in randomized controll
NBO, normobaric oxygen.manifested by transient or prolonged unconsciousness,
abnormal neurologic signs, cardiovascular dysfunction,
or severe acidosis, or for patients who are 36 years of
age or older and were exposed for 24 hours or more (in-
cluding intermittent exposures) or who have a COHb
level of 25% or more [26]. Four authors who are promin-
ent in this society have published similar recommenda-
tions [47].
In conclusion, HBO has a plausible but not compelling
rationale, is of unknown effectiveness, and has some
risks including that it might feasibly worsen neuro-
psychological sequelae. The risk/benefit will remain un-
clear until a large multi-center double-blind randomized
controlled trial examining long-term clinical outcomes is
performed; however, no such trials are currently regis-
tered as ongoing.
Pharmacological treatments
A diverse group of pharmacological treatments has been
investigated as treatment options in CO poisoning, with
the aim of decreasing the rate of neurological sequelae.
We have highlighted those agents that have already been
proven safe for use in humans for other indications.
Erythropoietin (EPO) is a cytokine that originally was
identified for its role in erythropoiesis and more recently
was shown to be produced in the central nervous sys-
tem. EPO offers neuronal protection when administered
systemically to animals with global and focal cerebral
ischemia. EPO administration led to substantial dose-
dependent reduction in S100B following CO poisoning
in an animal model [51]. A randomized prospective
study of 103 patients with CO poisoning compared sub-
cutaneous EPO for a week with placebo. S-100β levels
decreased more rapidly in patients in the EPO group,
and stroke scores were also better. At 30 days, fewered trials of hyperbaric oxygen therapy. HBO, hyperbaric oxygen;
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sequelae (12% versus 30%, P = 0.021) [52]. However,
enthusiasm should be tempered by the experience with
EPO in stroke, in which favorable small studies were
followed by a large negative study that showed a higher
death rate in the EPO arm [53].
Another novel treatment that has been repeatedly
studied in animals for acute CO poisoning is hydrogen-
rich saline. Hydrogen-rich saline is an anti-oxidant that
at this stage is currently used in Japan for human meta-
bolic disorders. It is non-toxic, convenient, and safe to
use. It has been shown in rat studies to decrease neu-
ronal necrosis and apoptosis, and improve neurobeha-
vioral function, following CO poisoning. Its suggested
mechanisms of action include reducing reactive oxygen
species levels and upregulating endogenous anti-
oxidative enzymes [54-56].
A diverse group of other substances has been tested in
animal studies and has shown possible benefit, including
granulocyte colony-stimulating factor, nimodipine, fruc-
tose diphosphate, hyperoxygenated solution and edara-
vone [57-60]. An even more diverse group of substances
has been shown to be effective in hypoxic/reperfusion
injury. The use of any of these agents cannot be recom-
mended outside of clinical trials; however, there may be
more rational treatments to test further in clinical trials
to prevent neurological damage from reactive oxygen
species than HBO.
Conclusions
The mainstay of management of CO poisoning involves
early 100% oxygen therapy. It is important to identify
patients at high risk of neuropsychological sequelae, and
the best established predictor is prolonged loss of con-
sciousness. However, new biomarkers such as S100B
show considerable potential to improve this prediction.
Better validated objective predictive tools would greatly
assist in the assessment of new and old treatments. The
benefits, risks, and indications for HBO remain unclear
despite six randomized controlled trials. Pharmacological
treatments that reduce reperfusion injury and apoptosis,
such as EPO, show considerable potential. These have a
stronger biological rationale and would be more widely
available, rapidly administered, and less expensive. Large
multi-center trials with objective and functional long-
term outcomes are needed for both old and new treat-
ments before they can be recommended.
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